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Objectives:We compared outcomes in post-menopausal estrogen receptor-positive (ER+)
breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) or neoadjuvant
chemotherapy (NACT).
Methods: We retrospectively identified post-menopausal women who received either
NAHT or NACT for non-metastatic, non-inflammatory, ER+, Her2neu negative breast can-
cer from 2004 to 2011. We compared long-term rates of locoregional relapse free survival
(LRFS), distant metastasis free survival (DMFS), and overall survival (OS) using the Kaplan–
Meier method.The Cox proportional hazards model was used to identify patient and disease
factors significantly associated with these endpoints.
Results:We identified 99 patients in our study, including 27 who received NAHT and 72 who
received NACT. There were no differences in 4-year LRFS, DMFS, or OS between groups.
On Cox proportional hazards modeling, the type of systemic therapy (NAHT versus NACT)
was not associated with OS. However, patients with progesterone receptor (PR) positive
disease had a 92% lower risk of death compared to patients with PR negative disease.
Conclusion: Our data suggest that outcomes are not adversely affected by NAHT in post-
menopausal women with ER+ breast cancer. Therefore, NAHT is a viable and potentially
less toxic option than NACT in appropriately selected patients. Furthermore, although PR
negative disease appears to be associated with poor prognosis, intensification of systemic
treatment with chemotherapy may not be associated with improvement of disease-related
outcomes in this patient population.
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INTRODUCTION
For patients with invasive cancers of the breast, both chemother-
apy and hormonal therapy are important components of definitive
treatment. Chemotherapy has been historically recommended for
breast cancer patients with tumors greater than 1.0 cm in size
and/or lymph node positive disease. Based on several random-
ized studies demonstrating a significant survival benefit in women
treated with tamoxifen, hormonal therapy is considered an addi-
tional component of standard therapy in women with hormone
receptor-positive disease (1).
Traditionally, both chemotherapy and hormonal therapy have
been given in the adjuvant setting. However, since the publica-
tion of the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-18 trial, chemotherapy has been increasingly admin-
istered before surgery in women with breast cancer (2). There are
several advantages to sequencing systemic therapy in this manner.
First, neoadjuvant chemotherapy (NACT) may facilitate surgery
in initially inoperable patients. Second, NACT may increase the
likelihood of breast conserving surgery (BCS) in patients present-
ing with large tumors. Third, the use of NACT enables clinicians
to directly observe the degree of tumor response to a specific
chemotherapy regimen, which may both guide further treatment
and provide prognostic information. Lastly, administering sys-
temic therapy, rather than surgery, initially may provide a theoret-
ical opportunity to eradicate microscopic circulating tumor cells
quickly and potentially prevent development of distant metastasis
in high risk patients.
The response of a tumor to NACT is largely dependent on
the systemic agents used and the tumor’s receptor status. Sev-
eral studies have demonstrated that “triple-negative” tumors [i.e.,
tumors that lack expression of estrogen receptor (ER), proges-
terone receptor (PR), and Her2neu] are more likely to exhibit a
www.frontiersin.org December 2013 | Volume 3 | Article 317 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marcus et al. Neoadjuvant therapy for breast cancer
pathologic complete response (pCR) to NACT compared to ER
and PR positive tumors (3, 4). Furthermore, of all molecular sub-
types, tumors expressing Her2neu have been shown to have the
highest rates of pCR, particularly when Her2neu-directed thera-
pies are included with their chemotherapy regimens (5). Based
on these findings, consensus guidelines have included low or
absent hormone receptor status as a factor in patient selection
for NACT (2, 6).
Contrary to triple-negative and Her2neu positive tumors,
breast tumors expressing ER and/or PR are frequently less sen-
sitive to chemotherapy than other tumor subtypes (7). Further-
more, having less than a pCR to NACT in patients with hormone
receptor-positive disease may not share the same prognostic sig-
nificance as it does in women with triple-negative or Her2neu
positive tumors (4). Due to the high proportion of ER and/or
PR positive tumors that exhibit little response to NACT, many
clinicians question the benefit of chemotherapy in patients with
hormone receptor-positive disease. Furthermore, studies validat-
ing the use of a 21-gene recurrence score assay (OncotypeDx)
support the notion that up to 50% of hormone receptor-positive
patients will not benefit from chemotherapy regardless of tumor
size and nodal status (8–10). However, recognizing the benefits
of upfront systemic therapy, many physicians are increasingly
prescribing neoadjuvant hormonal therapy (NAHT) to women
with hormone receptor-positive breast cancer as an alternative to
NACT, particularly in those who have co-morbidities precluding
chemotherapy treatment.
Nevertheless, prospective clinical data on the use of NAHT in
invasive breast cancer is scarce, and there are few studies compar-
ing NAHT and NACT in patients with estrogen receptor-positive
(ER+) breast cancers. The goal of our study was to compare long-
term outcomes of post-menopausal breast cancer patients with
ER+ tumors treated with NAHT versus those treated with NACT
followed by surgery.
MATERIALS AND METHODS
After obtaining approval from the Emory institutional review
board, we identified post-menopausal patients treated with NAHT
or NACT for non-metastatic, non-inflammatory, ER+, invasive
breast cancer at Emory University between 2004 and 2011. Patients
with tumors expressing Her2neu were excluded. Age greater than
50 was used as a surrogate for post-menopausal status in women
whose menopausal status was not recorded in the medical record.
None of the NAHT patients underwent adjuvant chemotherapy.
Patients who received systemic therapy but did not ultimately
undergo surgical resection of their tumor were excluded.
The delivery, type, dose, and duration of NAHT or NACT were
determined by the treating medical oncologist. Relevant patient,
tumor, and treatment characteristics were collected from the med-
ical record including patient age at diagnosis, tumor size (both
before and after neoadjuvant therapy), presence or absence of pCR
(defined as the absence of any invasive cancer in the breast and
lymph nodes in the pathologic specimen) (11), PR status, tumor
grade, lymphovascular space invasion, type of NAHT [tamoxifen
versus aromatase inhibitor (AI)], type of NACT (anthracycline-
based versus non-anthracycline-based), use of adjuvant radiation
therapy (XRT), and type of surgery (mastectomy versus BCS).
Locoregional recurrence free survival (LRFS), distant metasta-
sis free survival (DMFS), and overall survival (OS) were deter-
mined. LRFS was defined as time to either locoregional recurrence
(including failure in the ipsilateral breast, chest wall, or axillary,
supraclavicular, or internal mammary lymph nodes) or death, and
DMFS was defined as time to either distant metastasis or death.
Time to all endpoints was calculated from the date of pathologic
diagnosis of breast cancer.
All statistics were calculated using SAS Software, Version 9.3
(SAS, Cary, NC, USA). Pearson’s Chi-squared test was used to
determine whether differences in proportions existed between
groups with regard to baseline patient characteristics, unless
expected cell counts were less than 5, in which case Fisher’s Exact
test was used. The two-sample t -test was used to compare means
of continuous variables. The Wilcoxon test was used to compare
median values for continuous variables. Kaplan–Meier curves were
generated to evaluate survival, and time-to-event data between
groups was compared by the log-rank test. Cox proportional
hazards modeling was used to identify important patient and dis-
ease factors associated with primary and secondary endpoints. A
p-value of ≤0.05 was considered to be statistically significant.
RESULTS
PATIENT CHARACTERISTICS
Of the 99 patients included in the study, 72 (72.7%) received
NACT, and 27 (27.3%) received NAHT. Median age of all patients
was 59.0 years. As shown in Table 1, patients receiving NAHT
were older than patients receiving NACT (mean age 67.9 versus
58.0 years,p< 0.01),and patients receiving NAHT had lower grade
tumors (p= 0.03) and less advanced N stage (p< 0.01) compared
to patients receiving NACT.
TREATMENT
Among the NACT patients, the majority (50.8%) received both an
anthracycline and a taxane, while 38.1% received an anthracycline-
based regimen alone. Of patients receiving NAHT, 92.6% received
an AI, and 7.4% received tamoxifen. The median duration of
NAHT was 8.0 months (range 0.5–60.0 months).
OUTCOMES
Median follow-up for all patients was 45.7 months (range 2.8–
138.7 months). Very few patients developed a pCR. In fact, all
patients in the NAHT group were found to have residual disease at
the time of surgery, while in the NACT group, six patients (6.9%)
achieved a pCR. There was no statistically significant difference
in pCR rates between the two groups (p= 0.32). Mean tumor
shrinkage was 22.8% for patients receiving NACT and 23.0% for
patients receiving NAHT (p= 0.99). Rates of pathologic response
(either pCR or pathologic partial response) were 68.1% for NACT
patients and 80.0% for NAHT patients (p= 0.28). There was no
significant difference in median NAHT duration between NAHT
patients with pathologic response compared to those with no
pathologic response (7.5 versus 13.0 months, p= 0.57). Among
patients receiving NACT, rates of pathologic response were not
higher for patients receiving both an anthracycline and a tax-
ane (pathologic response seen in 71.4% of patients) compared
to patients receiving either an anthracycline alone (75.0%) or a
taxane alone (25.0%) (p= 0.19).
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Table 1 | Baseline patient characteristics for all patients receiving
either neoadjuvant chemotherapy (NACT) or neoadjuvant hormone
therapy (NAHT) prior to surgery for estrogen receptor-positive breast
cancer at Emory University between 2004 and 2011.
NACT NAHT p-Value*
n % n %
T stage 0.29
T1 12 16.9 8 30.8
T2 33 46.8 13 50.0
T3 22 31.0 5 19.2
T4 4 5.6 0 0.0
N stage <0.01
N0 20 29.9 17 63.0
N1 33 49.3 4 14.8
N2 11 16.4 4 14.8
N3 3 4.5 2 7.4
PR status 0.31
Positive 30 62.5 20 74.1
Negative 18 37.5 7 25.9
Tumor grade 0.03
Grade 1 14 24.6 4 19.1
Grade 2 23 40.4 15 71.4
Grade 3 20 35.1 2 9.5
Type of carcinoma 0.84
Ductal 40 62.5 18 66.7
Lobular 22 34.4 9 33.3
Mixed 1 1.6 0 0.0
Other 1 1.6 0 0.0
Adjuvant XRT 0.19
Yes 55 80.9 17 68.0
No 13 19.1 8 32.0
Mean age 58.0 67.9 <0.01
PR, progesterone receptor; XRT, radiation therapy.
*p-Values represent chi-squared test for all categorical variables and t-test for
comparison of means of continuous variables.
*p-Value calculated with chi-square test or Fisher’s Exact test where appropriate
for categorical variables. Two-sample t-test used for comparisons of mean age.
There were no differences in DMFS (4-year DMFS 90.0% for
NAHT versus 80.3% for NACT,p= 0.41) or OS (4-year OS 100.0%
for NAHT versus 85.9% for NACT, p= 0.49) between NAHT and
NACT patients (Figures 1 and 2). Cox proportional hazards mod-
eling identified PR status (HR= 0.08, 95% CI 0.01–0.68, p= 0.02)
as a significant predictor of OS, while advanced T stage (p= 0.96),
advanced N stage (p= 0.07), tumor grade (p= 0.09), and neoad-
juvant therapy type (NACT versus NAHT, p= 0.50) were not
significant factors for OS in the analysis. Risk of death was 92%
lower in the patients with PR positive disease compared to those
with PR negative disease. There were no significant differences in
LRFS between NAHT and NACT patients (p= 0.40). None of
the NAHT patients recurred locally, while two NACT patients
treated with mastectomy and no XRT developed locoregional
recurrence. Given the low overall event rate for local recurrence,
FIGURE 1 | Kaplan–Meier curves illustrating distant metastasis free
survival over time for patients receiving neoadjuvant hormonal
therapy (NAHT) versus neoadjuvant chemotherapy (NACT). Log-rank
p-value=0.41.
FIGURE 2 | Kaplan–Meier curves illustrating overall survival over time
for patients receiving neoadjuvant hormonal therapy (NAHT) versus
neoadjuvant chemotherapy (NACT). Log rank p-value=0.49.
distant recurrence, and death, multivariate analysis was unable to
be performed.
DISCUSSION
Findings from our study support the use of NAHT in select
post-menopausal breast cancer patients with ER+ disease. In this
patient cohort, PR negativity was a predictor of poor outcome,
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but tumor grade, N stage, patient age, and the type of neoadju-
vant systemic therapy (NAHT versus NACT) were not. Although
NACT patients were younger and had more advanced stage disease,
there were no differences in LRFS, DMFS, or OS between patients
treated with NAHT and NACT, suggesting that NACT may poten-
tially mitigate the effects of these risk factors on outcome. While
NACT appears warranted in these patients with high risk disease,
NAHT alone may be sufficient in older women with less advanced
ER+ breast cancer.
As noted previously, there is very little available data comparing
long-term outcomes in women treated with modern NAHT and
NACT. Moreover, the majority of published data on NAHT alone
pertains to patients who are either unable to tolerate chemotherapy
or have a short life expectancy that precludes chemotherapeutic
treatment. While pCR rates associated with NAHT are generally
low, our study and other research suggest that NAHT may be an
effective therapy in appropriately selected patients. In one prospec-
tive Phase II study involving 94 breast cancer patients with oper-
able breast tumors measuring at least 4 cm, all patients received
NAHT, with NACT reserved for tumors that failed to respond
to NAHT and for tumors not expressing ER. This study was not
limited to post-menopausal patients with ER+ disease, and the
majority of NACT patients were treated with cyclophosphamide,
doxorubicin, vincristine, and prednisolone, a chemotherapy regi-
men no longer used in standard practice. Nevertheless, pCR rates
were similar to what we found in our cohort with none of the
NAHT patients and only eight NACT patients achieving a pCR.
In spite of the relatively low pathologic response rate, there was
no difference in OS between patients who received NAHT alone
and those who received NACT after a median follow-up period of
7.5 years (12). Additionally, a randomized phase II study from Rus-
sia demonstrated that NAHT was associated with rates of objective
response and BCS that were comparable to those of NACT in 121
post-menopausal patients with ER+ or PR+ breast cancers (13).
However, this study did not evaluate local control, rates of dis-
tant metastasis, or survival, and to date there is remarkably little
data describing whether NACT and NAHT are associated with
comparable results in terms of disease outcomes in this patient
population.
Given the paucity of data comparing the use of NAHT to NACT
for hormone sensitive breast cancer and outcome, the results of
our study may help guide decision-making regarding neoadjuvant
therapy in post-menopausal breast cancer patients with ER+ dis-
ease. The primary limitation of our study is its retrospective nature,
which potentially introduces a selection bias in terms of the type of
neoadjuvant therapy delivered. The small numbers of patients and
limited follow-up also preclude definitive conclusions,but our data
(along with the other small studies noted previously) support the
notion that NAHT may be an effective alternative to NACT. Fur-
thermore, although the type of NAHT was fairly homogenous, the
duration of therapy varied widely, which may have had an effect
on the efficacy of the treatment (although NAHT duration did
not appear to influence outcome). Within the cohort who received
NACT, there was also variability in the type of chemotherapy deliv-
ered, with 50.8% of patients receiving both an anthracycline and
a taxane and 38.1% of patients receiving an anthracycline alone.
Finally, although the majority of baseline patient characteristics
were balanced between groups, patients receiving NACT had more
advanced N stage and higher grade tumors compared to patients
receiving NAHT, which is consistent with the current practice of
delivering NACT in patients with aggressive disease. These imbal-
ances between treatment groups indicate possible selection bias,
and the variability in the type and duration of systemic therapy
within the groups may further preclude definitive conclusions
about the efficacy of NAHT versus NACT. Based on these lim-
itations, in addition to the small size of the cohort and limited
follow-up, our results must be interpreted with caution. Nonethe-
less, the findings of our study are provocative and merit further
exploration, ideally in the setting of a prospective randomized trial.
The results of our study demonstrate encouraging effective-
ness of NAHT, with no differences in LRFS, DMFS, or OS found
between patients receiving NAHT and those receiving NACT. Fur-
thermore, while PR negativity appears to be associated with poor
prognosis, intensification of systemic treatment may not be associ-
ated with improvement of disease-related outcomes in this patient
population. Although prospective data is needed to confirm these
results, our data suggest that NAHT is a viable treatment option for
appropriately selected post-menopausal patients with ER+ breast
cancer.
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